- Results showed 100% sensitivity and reduced time to diagnosis by an estimated 65.5%, with potential to improve pathologists’ workflow in a real-world environment -Brazil-based Grupo Oncoclinicas is ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

A team of researchers in Sweden has discovered that an artificial intelligence platform is capable of accurately diagnosing prostate cancer in tissue samples, offering the potential to speed up ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time. The FDA approved capivasertib, sold as Truqap by AstraZeneca, on June 12, ...

Many published studies assess algorithms retrospectively, using historical datasets rather than active patient workflows.

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

(HealthDay)—Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a higher risk for adverse ...

The US Food and Drug Administration (FDA) has authorized marketing of artificial intelligence (AI) software to help pathologists detect prostate cancer. The program, called Paige Prostate, is the ...